急性呼吸不全を合併した免疫不全患者に対する呼吸療法がICU転帰に与える影響 : NPPVとHFNCの比較

機関リポジトリ Web Site オープンアクセス

書誌事項

タイトル別名
  • キュウセイ コキュウ フゼン オ ガッペイ シタ メンエキ フゼン カンジャ ニ タイスル コキュウ リョウホウ ガ ICU テンキ ニ アタエル エイキョウ : NPPV ト HFNC ノ ヒカク
  • Comparison of noninvasive positive pressure ventilation and high-flow nasal cannula for immunocompromised patients with acute respiratory failure
  • 免疫不全患者に対するHFNC

この論文をさがす

説明

Background : Non-invasive positive pressure ventilation （NPPV） is highly recommended for immunocompromised patients with acute respiratory failure. In this population it remains uncertain, however, whether high flow nasal canula（HFNC）is as beneficial as NPPV. Methods : We retrospectively studied immunocompromised patients with acute respiratory failure admitted to our ICU from ２０１１ to ２０１８. The background and clinical outcomes of patients initially treated with HFNC and NPPV were compared. Results : Upon admission, １２ patients were treated with HFNC and １０ with NPPV. While the length of ICU stay was significantly shorter in HFNC group （HFNC４．６days vs. NPPV１３．８days, p=０．０２）, no intergroup difference was seen in ICU mortality （１６．７％ vs.３０．０％, p=０．４６）or intubation rate（３３．３％ vs.５０．０％, p=０．４３）. Conclusions : For immunocompromised patients with acute respiratory failure, HFNC may be an alternative to NPPV. Further prospective investigation is warranted.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ